FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

MAHA Stack

Immune Supportintermediate

82

synergie

82
Share
Pépétides

3

Moyenne journalière en mcg

2,600

Niveau

intermediate

Ajouté

May 17, 2026

Aperçu

The MAHA Stack — inspired by RFK Jr.''s "Make America Healthy Again" movement and his public advocacy for peptide access — combines three of the most evidence-backed peptides into a foundational health optimization protocol covering healing, immunity, and cognitive function. After HHS Secretary RFK Jr.'s February 2026 signal of intent to reconsider the restricted peptide list — followed by the FDA formally removing 12 peptides from the Category 2 list in April 2026 (removal is not the same as approval, and the peptides remain under PCAC review) — this combination became one of the most searched peptide stacks online. BPC-157 provides systemic healing support — gut mucosal repair, connective tissue regeneration, anti-inflammatory action, and neurotropic effects across the gut-brain axis. Its broad mechanism makes it a foundational health compound rather than a specialized treatment. Thymosin Alpha-1 is an immune modulator originally isolated from the thymus gland. Unlike crude immune "boosters," it precisely calibrates immune function — enhancing the response against pathogens and abnormal cells while reducing excessive inflammatory signaling that drives autoimmune-type conditions. It activates dendritic cells, NK cells, and T-helper cells while modulating cytokine production. Thymosin Alpha-1 has FDA-approved use in some countries for hepatitis and is extensively studied for chronic fatigue, autoimmune conditions, and cancer immunotherapy support. Semax adds the cognitive and neural component — BDNF upregulation, dopaminergic support, and neuroprotection. This is consistent with the MAHA movement''s emphasis on brain health and cognitive function as core components of overall health. Together, this stack represents a "whole-system" approach: healing the body''s physical tissue, calibrating immune function, and supporting the brain — the three systems most impacted by modern inflammatory lifestyles.

Protocole de dose

BPC-157

Twice per day· subcutaneous

Lire plus sur BPC-157 →

250 mcg

par dose

Thymosin Alpha-1

2x per week· subcutaneous

Lire plus sur Thymosin Alpha-1 →

1,500 mcg

par dose

Semax

Every day· intranasal

Lire plus sur Semax →

600 mcg

par dose

Objectifs & Preuves

Whole-system healthImmune calibrationHealingCognitive functionInflammation reduction
Niveau d'évidence :Données humaines

Avertissements

  • BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review (July 23, 2026) — not legal to compound yet. Stack peptides individually before combining if new to peptide therapy.

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.